

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 30, 2022 (the “**Prospectus**”) of Beauty Farm Medical and Health Industry Inc. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended from time to time, (the “**U.S. Securities Act**”)) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any applicable state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.



贝黎诗
PALAISPA

CellCare
[秀|可|儿|医|美]

NEOLOGY
研源医疗

Beauty Farm Medical and Health Industry Inc.
美麗田園醫療健康產業有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2373)

**FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,
STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by the Overall Coordinators (for themselves and on behalf of the Capital Market Intermediaries and the International Underwriters) on February 3, 2023 (after trading hours), in respect of an aggregate of 6,080,000 Shares (the “**Over-allotment Shares**”), representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to facilitate the return to LIY Management Holdings Limited of the 6,080,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocation under the International Offering.

* For identification purposes only

The Over-allotment Shares will be issued and allotted by the Company at HK\$19.32 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the stabilization period in connection with the Global Offering ended on Sunday, February 5, 2023, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of the stabilizing actions undertaken by Morgan Stanley Asia Limited, as the Stabilizing Manager, or any person acting for it, during the stabilization period is set out in this announcement.

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was fully exercised by the Overall Coordinators (for themselves and on behalf of the Capital Market Intermediaries and the International Underwriters) on February 3, 2023 (after trading hours), in respect of an aggregate of 6,080,000 Shares, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option to facilitate the return to LIY Management Holdings Limited of the 6,080,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocation under the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$19.32 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in such Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on February 8, 2023.

Share Capital upon the Completion of the Full Exercise of Over-allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the full exercise of the Over-allotment Option is set out below:

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
LIY Holdings Limited	2,000,000	0.87%	2,000,000	0.85%
LIY Management Holdings Limited ⁽¹⁾	35,560,000	15.42%	35,560,000	15.03%
LIFY Management Holdings Limited	42,400,000	18.39%	42,400,000	17.92%
MeiYao Holdings Limited	35,020,000	15.19%	35,020,000	14.80%
Beijing Xinyu Meiye Holdings Limited	57,939,000	25.13%	57,939,000	24.48%
Crest Sail Limited	7,300,000	3.17%	7,300,000	3.08%
Thriving Team Limited	6,185,568	2.68%	6,185,568	2.61%
Individual Group Holdings Limited	3,240,000	1.41%	3,240,000	1.37%
ZYLot Holdings Limited	400,000	0.17%	400,000	0.17%
Cornerstone Investors				
– TruMed	6,797,500	2.95%	6,797,500	2.87%
– Botanee	2,818,500	1.22%	2,818,500	1.19%
– Juzi Holding	4,027,000	1.75%	4,027,000	1.70%
– Harvest	8,054,000	3.49%	8,054,000	3.40%
Other Public Shareholders	18,839,500	8.17%	24,919,500	10.53%
Total ⁽²⁾	<u>230,581,068</u>	<u>100%</u>	<u>236,661,068</u>	<u>100%</u>

Notes:

- (1) Inclusive of the 6,080,000 Shares borrowed by Morgan Stanley Asia Limited, the Stabilizing Manager, or any person acting for it, under the Stock Borrowing Agreement.
- (2) Any discrepancies in the table between the totals and the sums of the amounts listed therein are due to rounding.

Use of Proceeds

The additional net proceeds of approximately HK\$112.2 million to be received by the Company from the allotment and issue of the Over-allotment Shares after deducting the underwriting commissions and other estimated expenses in connection with the exercise of the Over-allotment Option, will be used by the Company, on a pro rata basis, for the purposes as set out in the section headed “Future Plans and Use of Proceeds – Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the stabilization period in connection with the Global Offering ended on Sunday, February 5, 2023, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Morgan Stanley Asia Limited, as the Stabilizing Manager, or any person acting for it, has undertaken the following stabilizing actions during the stabilization period:

- (1) over-allocation of an aggregate of 6,080,000 Offer Shares in the International Offering, representing approximately 15.0% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) the borrowing of an aggregate of 6,080,000 Shares from LIY Management Holdings Limited pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering; and
- (3) the full exercise of the Over-allotment Option by Overall Coordinators (for themselves and on behalf of the Capital Market Intermediaries and the International Underwriters) on February 3, 2023 (after trading hours), in respect of an aggregate of 6,080,000 Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price of HK\$19.32 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Share under the Global Offering.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the full exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) of the Listing Rules.

By order of the Board
Beauty Farm Medical and Health Industry Inc.
Li Yang
Chairman

Hong Kong, February 5, 2023

As at the date of this announcement, the Board comprises Mr. Li Yang as Chairman and executive Director, Mr. Lian Songyong as executive Director, Mr. Zhai Feng, Mr. Geng Jiaqi and Ms. Li Fang Yu as non-executive Directors and Mr. Fan Mingchao, Mr. Liu Teng and Mr. Jiang Hua as independent non-executive Directors.